<DOC>
	<DOCNO>NCT00002784</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . It yet know high-dose combination chemotherapy plus peripheral stem cell transplantation effective standard combination chemotherapy breast cancer . PURPOSE : Randomized phase III trial compare high-dose combination chemotherapy plus peripheral stem cell transplantation standard combination chemotherapy treat woman stage II stage III breast cancer .</brief_summary>
	<brief_title>High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy Treating Women With High-Risk Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare survival , disease-free survival , systemic disease-free survival woman high-risk , operable stage II/III breast cancer treat three course dose-intensive epirubicin/cyclophosphamide ( EC ) support granulocyte colony-stimulating factor ( G-CSF ) G-CSF-mobilized peripheral blood stem cell vs. standard EC follow cyclophosphamide/methotrexate/fluorouracil . II . Compare toxicity , duration quality-adjusted time without symptom toxicity , quality life associate two treatment . III . Evaluate cost effectiveness two treatment . OUTLINE : This randomize study . Patients stratify estrogen receptor status menopausal status . Within 6 week surgery , patient first group receive epirubicin ( prefer ) doxorubicin plus cyclophosphamide every 3 week 4 course follow conventional cyclophosphamide , methotrexate , fluorouracil ( CMF ) every 4 week 3 course . Patients second group undergo stem cell mobilization harvest granulocyte colony-stimulating factor ( G-CSF ) follow within 10 week surgery high-dose chemotherapy epirubicin cyclophosphamide follow peripheral blood stem cell rescue G-CSF . All patient receive adjuvant tamoxifen , patient underwent lumpectomy prior entry require receive adjuvant radiotherapy ( radiotherapy optional patient underwent mastectomy prior entry ) . Patients follow every 3 month 2 year , q 6 month 3 year , yearly . PROJECTED ACCRUAL : 210 patient accrue 4 year provide 195 evaluable patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven breast carcinoma one follow category : 10 involved axillary node 5 involved axillary node either : Primary tumor estrogen receptor ( ER ) negative ( less 10 femtomoles per milligram cytosol protein ) T3 tumor ( regardless ER status ) Total mastectomy breastconserving procedure ( lumpectomy quadrantectomy ) require within 6 week prior randomization Tumor confine breast axillary node ( T1ac , T2 , T3 , N12 , M0 UICC stag system ) The following condition exclude entry : Satellite skin nodule distant primary tumor Supraclavicular node involvement Inoperable , mat axillary node Fixation primary tumor chest wall ( exclude pectoralis major ) Bilateral breast cancer ( mass opposite breast unless biopsyproven benign ) Hot spot bone scintigram ( unless confirm benign ) Skeletal pain unknown cause Hormone receptor status : ER status determination prefer , require PATIENT CHARACTERISTICS : Age : 1665 Sex : Women Menopausal status : Any status Performance status : ECOG 02 Hematopoietic : WBC least 4,000 Platelets least 100,000 Hepatic : Bilirubin great 1.1 mg/dL ( 20 micromoles/L ) AST great twice normal Renal : Creatinine great 1.3 mg/dL ( 120 micromoles/L ) Cardiovascular : Left ventricular ejection fraction great 50 % MUGA Other : No second malignancy except : Basal cell carcinoma Adequately treat carcinoma situ cervix No significant nonmalignant disease would preclude participation No psychiatric addictive disorder would compromise informed consent participation No pregnant nursing woman Adequate contraception strongly advise fertile woman PRIOR CONCURRENT THERAPY : No prior therapy breast cancer surgery ( see Disease Characteristics )</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>